Total operating expenses 404,164 276,404 39,445
---------- ----------- -----------
Income (loss) from operations (183,259) 30,858 4,404
Other income (expenses):
Late fees related to social
security insurance (446) (213) (30)
Government grants 14,628 3,864 551
Financial expenses - net (12,968) (6,573) (938)
Fair value changes of warrant
liability 6,851 315 45
Other income (expense) - net (149) (6,454) (921)
Total other income (expense) - net 7,916 (9,061) (1,293)
---------- ----------- -----------
Income (loss) before income taxes (175,343) 21,797 3,111
Income tax benefit (expense) 820 (1,218) (174)
---------- ----------- -----------
Net income (loss) (174,523) 20,579 2,937
---------- ----------- -----------
Net income (loss) attributable to
Lakeshore Group (174,523) 20,579 2,937
========== =========== ===========
Net income (loss) (174,523) 20,579 2,937
Other comprehensive income
(loss): Foreign currency
translation adjustment 3,166 (4,900) (700)
---------- ----------- -----------
Total comprehensive income (loss) (171,357) 15,679 2,237
========== =========== ===========
Earnings (loss) per share:
-- Basic and Diluted (1.88) 0.11 0.02
========== =========== ===========
Weighted average number of
ordinary shares outstanding:
-- Basic and Diluted 93,058,197 190,429,732 190,429,732
========== =========== ===========
Lakeshore Biopharma Co., Ltd
Unaudited Reconciliations of Non-GAAP Results
(All amounts in thousands)
Six Months Ended September 30,
-----------------------------------
2023 2024 2024
------------- ---------- -------
RMB RMB US$
Net income (loss) (174,523) 20,579 2,937
Add: income tax expense (benefit) (820) 1,218 174
Add: financial expenses - net 12,968 6,573 938
Add: depreciation and amortization 23,734 25,414 3,627
------------- ---------- -------
EBITDA (138,641) 53,784 7,676
============= ========== =======
Add: Share-based compensation
expenses - 1,659 237
Add: late fees related to social
security insurance 446 213 30
Add: other income (expense) - net 149 6,454 921
Add: fair value changes of warrant
liability (6,851) (315) (45)
Add: government grants (14,628) (3,864) (551)
------------- ---------- -------
Adjusted EBITDA (159,525) 57,931 8,268
============= ========== =======
Six Months Ended September 30,
-----------------------------------
2023 2024 2024
------------- ---------- -------
RMB RMB US$
Net income (loss) (174,523) 20,579 2,937
Add: share-based compensation
expenses - 1,659 237
Add: loss on disposal of property,
plant and equipment - 8,210 1,172
------------- ---------- -------
Adjusted net income (loss) (174,523) 30,448 4,346
============= ========== =======
View original content:https://www.prnewswire.com/news-releases/lakeshore-biopharma-reports-unaudited-financial-results-for-the-first-half-of-fiscal-year-2025-and-updates-full-year-guidance-302336215.html
SOURCE LakeShore Biopharma
/CONTACT: Yiyang Wang, ir@lakeshorebio.com
(END) Dow Jones Newswires
December 19, 2024 09:05 ET (14:05 GMT)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.